Global Insomnia Market, By Therapy Type (Non-pharmacological and Pharmacological Therapy, Drug Class (Melatonin Antagonist, Antidepressants, Benzodiazepines, No benzodiazepines and Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy and Retail Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Insomnia Market
Insomnia market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.4% in the above mentioned forecast period. The factors driving this market's growth are emerging markets and massive investment in research and development.
Insomnia is a sleep disorder in which a person finds it difficult to sleep or stay asleep. Low stamina, daytime sleepiness, depression, and irritability are among the symptoms. It is a very common disorder that affects millions of people all over the world. Circadian rhythm disruption, chronic pain, hyperthyroidism, menopause, psychological stress, and other medical conditions all contribute to insomnia. Furthermore, excessive use of drugs such as caffeine, alcohol, and nicotine may result in insomnia. Various diagnostic devices are used in sleep laboratories to diagnose this disorder.
Rising stress levels, the presence of patented molecules in the market, potential drugs in the clinical pipeline, the introduction of technologically advanced medical devices, and the growing geriatric population are all factors influencing the growth of the insomnia therapeutics market. Growing awareness about the impact of sleep deprivation on daily life is expected to increase the adoption rate of various insomnia treatments, resulting in revenue growth for the insomnia therapeutics market.
Other factors, such as side effects from certain over-the-counter and prescription medications, arthritis, and excessive use of media devices before bed, are increasing the number of people suffering from insomnia, boosting market growth prospects. Furthermore, the rise in psychological disorders and the ever-increasing noise levels in cities will drive the insomnia treatment market during the forecast period. Furthermore, emerging markets and significant investment in research and development are driving this market's growth.
However, misconceptions about the seriousness of insomnia, as well as patient non-adherence to treatment, are among the factors expected to limit market growth over the forecast period. Dearth of skilled medical professionals and lack of a strong healthcare infrastructure in the backward economies are further derailing the market growth rate
This insomnia market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the insomnia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Insomnia Market Scope and Market Size
The insomnia market is segmented on the basis of therapy type, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of therapy type, the global insomnia market is segmented into non-pharmacological and pharmacological therapy
- Based on drug class, the global insomnia market is segmented into melatonin antagonist, antidepressants, benzodiazepines, non-benzodiazepines and others.
- Route of administration segment for global insomnia market is categorized into oral, parenteral and others.
- On the basis of end-users, the global insomnia market is segmented into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the global insomnia market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.
Insomnia Market Country Level Analysis
Insomnia market is analysed and market size information is provided by the country, therapy type, drug class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the insomnia market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the global insomnia market and will flourish its dominance over the forecast period because of global leaders in research and development activities, an established approval process framework, an increase in the number of FDA-approved drugs and rise in the patient suffering from mental illness. Asia-Pacific is projected to score the highest growth rate owing to the developing healthcare facilities, a large number of generic manufacturers, and an increase in government initiatives and specialist communities.
The country section of the insomnia market report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Insomnia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to insomnia market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the insomnia market in the growth period.
Competitive Landscape and Insomnia Market Share Analysis
Insomnia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global insomnia market research.
Some of the major players operating in the insomnia market are Takeda Pharmaceutical Company Limited., Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Endo International plc, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Lupin., Cipla Inc., Aurobindo Pharma., Torrent Pharmaceuticals Ltd, Alvogen., Merck Sharp & Dohme Corp., Apotex Inc., Zydus Cadila., Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited and HIKAL Ltd. among others.
SKU-